no desc

Fixed-dose combination of beta-blocker and ACEi : for which hypertensive patients?

Background Vimeo Live Event

About the event

Today, due to Covid situation, High HR is now considered as an independent risk factor, this combined with HTN multiplies the risk and elevated BP is a leading contributor to premature death, that´s why are so special beta-blockers in combination with angiotensin-converting enzyme (ACE) inhibitors thanks to their complementary mode of action on the sympathetic nervous system and renin–angiotensin–aldosterone system, two interlinked pathways that influence cardiovascular risk and disease outcomes.

The lecture of Prof. Hall was focused on the needs to control both BP and HR in the HTN patient with high HR including where guidelines supports the use of beta-blocker/ACEI combination – Cosyrel, the first and only SPC of a BB + Coversyl".

Ref: Williams B et al. Eur Heart J. 2018;39(33):3021-3104. NCD Risk Factor Collaboration (NCD-RisC). Lancet. 2017;389:37–55. 2. Williams B et al. Eur Heart J. 2018;39(33):3021-3104. 3. Palatini P et al. J Hypertens. 2016;34⁵:813-821. 4. Sinski M et al. Curr Pharm Des. 2017;23(31):4626-4634. Madej A et al. Int J Clin Pharmacol Ther. 2009;47(11):686-694. Coversyl 5mg is indicated for Treatment of hypertension, heart failure and stable coronary artery disease. Coversyl 10mg is indicated for Treatment of hypertension and stable coronary artery disease.
Background Vimeo Live Event

Don't miss our next events!

Subscribe to our newsletter to receive invitations to upcoming events

You can unsubscribe at any time by clicking on the link in our emails.
SERVIER CENTRAL AMERICA AND THE CARIBBEAN, S.A.Edificio Dream Plaza, Costa Del Este, Ciudad de Panamá, Panamá+507-301-0227Todo el contenido de este sitio web, es sólo para los profesionales de la salud y un uso interno del evento.
LogoCopyright © 2022 Servier University by SERVIER CENTRO AMÉRICA Y EL CARIBE, S.A.